PEPTINOVO BIOPHARMA
Peptinovo develops novel nanoparticles targeting anti-cancer drugs to tumors for improved therapeutic outcomes and reduced side effects. The company has strong knowledge of the drug discovery and development process gained during the many years the founders worked for large pharmaceutical companies.
PEPTINOVO BIOPHARMA
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2014-01-01
Address:
Ann Arbor, Michigan, United States
Country:
United States
Website Url:
http://www.peptinovo.com
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Global Site Tag
Similar Organizations
HelioWave Technologies
HelioWave Technologies is leveraging innovative microfluidic-based systems to revolutionize the way of sterility of biopharma products.
Current Employees Featured
Founder
Official Site Inspections
http://www.peptinovo.com
- Host name: box2542.bluehost.com
- IP address: 50.87.180.88
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "Peptinovo Biopharma"
Peptinovo Biopharma Inc. – Improving Cancer Survival …
Peptinovo’s seasoned team has launched three drugs from idea to market, started seven individual pharma companies with 3 exits and 4 ongoing compaines, and led all aspects needed to develop, test, and launch …See details»
About us – Peptinovo Biopharma Inc.
Peptinovo Biopharma is a pre-clinical biotechnology company, founded by two experienced biotech startup entrepreneurs who have successfully created and exited from previous biotech start-ups. Our StorySee details»
Peptinovo Biopharma - Crunchbase Company Profile
Peptinovo develops novel nanoparticles targeting anti-cancer drugs to tumors for improved therapeutic outcomes and reduced side effects. The company has …See details»
Our Story – Peptinovo Biopharma Inc.
Ren self-funded the company and the Peptinovo Biopharma company started by applying for NIH grants in 2014. What started in a small lab in Ann Arbor, Michigan, ultimately lead to the development of the patented breakthrough …See details»
Peptinovo Biopharma - Company Profile
Peptinovo is developing its first platform, PNB-281, to eliminate the nerve damage caused by paclitaxel against many major cancers including breast, ovarian, lung, prostate, and pancreatic …See details»
Peptinovo Biopharma 2025 Company Profile: …
Mar 18, 2021 Peptinovo Biopharma General Information Description. Operator of a smart drug delivery company intended to improve cancer survival. The company helps in the discovery and development of chemotherapy drugs that …See details»
PEPTINOVO BIOPHARMA INC. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for PEPTINOVO BIOPHARMA INC. of Ann Arbor, MI. Get the latest business insights from Dun & Bradstreet.See details»
Peptinovo Biopharma - Funding, Financials, Valuation & Investors
Peptinovo Biopharma has raised a total of . obfuscated. obfuscated. in funding over 1 round. This was a Venture - Series Unknown round raised on Sep 24, 2024. ... How much funding has this …See details»
Peptinovo Biopharma - Overview, News & Similar companies
Peptinovo Biopharma contact info: Phone number: (734) 330-0265 Website: www.peptinovo.com What does Peptinovo Biopharma do? Peptinovo is developing its first platform, PNB-281, to …See details»
Peptinovo Biopharma - Org Chart, Teams, Culture & Jobs - The Org
View Peptinovo Biopharma's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. This is an unverified …See details»
Peptinovo Biopharma - Products, Competitors, Financials, …
Peptinovo Biopharma engages in biopharmaceutical solutions improving cancer treatment through its drug delivery platform. Use the CB Insights Platform to explore Peptinovo Biopharma's full …See details»
Peptinovo Biopharma - Cantilever Investors
Peptinovo offers a targeted drug-delivery platform Peptide-Amphiphile Lipid Micelle (PALM) that reduces or eliminates chemotherapy-induced peripheral neuropathy (CIPN), a serious side …See details»
Peptinovo Biopharma - VentureRadar
Peptinovo’s patented technology offers a smart drug delivery platform designed to improve the efficacy of a variety of proven, approved chemotherapies on a broad range of solid tumors …See details»
Revolutionizing Cancer Treatment: Peptinovo Biopharma Secures …
Dec 16, 2024 Peptinovo Biopharma Inc., a trailblazer in innovative cancer treatment solutions, has successfully raised $1,400,000 in its latest round of funding, a critical milestone for this …See details»
PEPTINOVO BIOPHARMA INC. Company Information - Funding, …
Peptinovo biopharma inc. Chemotherapy is the foundation of cancer treatment because it is so effective, but it is also the downfall of cancer treatment because it is so toxic. Patients can …See details»
Ren Homann – Peptinovo Biopharma Inc.
Dr. Ren Homan, Ph.D. (Founder) is an experienced biotech entrepreneur with 30 years of drug discovery and development experience at Parke-Davis, Pfizer, and Esperion Therapeutics. …See details»
Varnum Represents Biotech Firm in $10M Series A Round
Dec 16, 2024 Peptinovo Biopharma (Peptinovo), an Ann Arbor-based biopharma company, has announced the successful initial close of its Series A funding round, raising $1.4 million. This …See details»
Peptinovo Biopharma on Silicon Prairie Online 2025
Mar 12, 2025 Peptinovo Biopharma, with a valuation of $19 million, is raising funds on Silicon Prairie Online. The company has developed a smart drug-delivery platform designed to …See details»
Our Pipeline – Peptinovo Biopharma Inc.
The Peptinovo team has developed three other leading chemotherapy drugs (Tubulin Disruptors, Platinum Drugs and Gemcitabine) leveraging the PALM™ Technology Platform. Our goal is to …See details»
Peptinovo Biopharma secures $1.4M to advance cancer tech
Dec 19, 2024 Peptinovo is now forming a syndicate to finance the remaining $8.6 million in the round and is on pace to begin the clinical trial process in the first quarter of 2025. By Anna …See details»